Harpreet Singh (file photo)
TCR-focused Immatics adds another marquee name to its list of partners: GSK
Immatics, in its fecund deal spree, has lured GSK, as the British drugmaker refocuses its attention to the lucrative field of oncology.
On Thursday, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
